{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Angiogenesis > ToceranibCAS：356068-94-5
Molecular Formula：C22H25FN4O2
Molecular Weight：396.46
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Yellow to orange Solid
Qty：
Size：
| CAS | 356068-94-5 |
| Name | Toceranib |
| Molecular Formula | C22H25FN4O2 |
| Molecular Weight | 396.46 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | Yellow to orange Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD16038046 |
| SMILES | CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)C=C3C4=C(C=CC(=C4)F)NC3=O |
| InChIKey | SRSGVKWWVXWSJT-ATVHPVEESA-N |
| InChI | InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6，11-12，25H，3-4，7-10H2，1-2H3，(H，24，29)(H，26，28)/b17-12- |
| PubChem CID | 5329106 |
| Target Point | PDGFR;VEGFR;c-Kit |
| Passage | Angiogenesis; Protein Tyrosine Kinase/RTK |
| Background | It is a receptor tyrosine kinase (RTK) inhibitor, which can effectively inhibit PDGFR, VEGFR, Kit, has anti-tumor and anti-angiogenic activities, and can be used in the study of canine mast cell tumors. |
| Biological Activity | Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor， and it potently inhibits PDGFR， VEGFR， and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR， respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity， and used in the treatment of canine mast cell tumors.[1-3] |
| Data Literature Source | [1]. London CA， et al. Phase I dose-escalating study of SU11654， a small molecule receptor tyrosine kinase inhibitor， in dogs with spontaneous malignancies. Clin Cancer Res. 2003 Jul;9(7):2755-68. [2]. Halsey CH， et al. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia?) in canine mast cell tumor. BMC Vet Res. 2014 May 6;10:105. [3]. Mitchell L， et al. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med. 2012 Mar-Apr;26(2):355-62. |
| Unit | Bottle |
| Specification | 5mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
